



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Thursday January 29, 2004 | 9:05 am ET

Recom Receives FDA Approval

LOS ANGELES--(BUSINESS WIRE)--Jan. 29, 2004--Recom Managed Systems, Inc. (OTCBB:RECM - News) announces that it has received approval from the Food and Drug Administration to proceed with the sales and marketing of its first medical device -- a 12-lead, 24-hour ECG medical device that the Company believes is the premier ambulatory 12-lead ECG device in the industry.

The FDA letter, dated January 28, 2004, provides that the Company may "market the device" subject to requirements of "annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration." The FDA approval further provides that the "FDA may publish further announcements concerning your device in the Federal Register."

The Company's FDA approval outlines many legal provisions that the Company is obligated to comply with, and an outline of these obligations is available by review of the FDA letter that will be available on the Company's website (www.recom-systems.com) as soon as practicable.

Marvin Fink, the Company's CEO, commented: "The Company's FDA approval of its revolutionary ECG device is gratifying to me personally. I have worked very hard on this. I would like to thank our entire Board of Directors, and our staff. Most importantly, I must thank our CTO, Budimir Drakulic, without whose vision this would never have happened. This is a serious and unparalleled event for this young and exciting Company."

About Recom Managed Systems

Recom Managed Systems, Inc., a Delaware corporation, is an emerging life sciences company. In September 2002, Recom completed a technology acquisition for purposes of attempting to develop and then commercialize heart-monitoring devices. Although the Company has just received 510k approval on its first device from the FDA, Recom intends for the foreseeable future to remain a development-stage company with limited cash and/or other tangible assets and no immediate prospects of revenue. Recom may possibly require some additional money to fund further development and continue with attempts to commercialize the technology into products and services. Recom cannot provide assurances that any of these endeavors will be successful.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.

Contact:

Recom Managed Systems, Inc.
Rodney Hildebrandt: 864-233-2300
Fax: 864-233-2100
www.recom-systems.com

Source: Recom Managed Systems, Inc.